Inspire Medical Systems
continued to expand evidence for its next-generation hypoglossal nerve stimulation therapy for obstructive sleep apnea, presenting final ADHERE registry results covering more than 5,000 patients and the OSPREY randomized trial broadening neurostimulation options at SLEEP 2026 in June.
- Country
- United States
- Ticker
- INSP
FDA approved
Hypoglossal nerve stimulation
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bioelectronic medicine & neuromodulation | regenerative-personalized | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.